Cargando…

Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease

Human ubiquitin carboxyl-terminal hydrolase-2 (USP2) inhibitors, such as thiopurine analogs, have been reported to inhibit SARS-CoV papain-like proteases (PLpro). The PLpro have significant functional implications in the innate immune response during SARS-CoV-2 infection and considered an important...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirza, Muhammad Usman, Ahmad, Sarfraz, Abdullah, Iskandar, Froeyen, Matheus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487165/ https://www.ncbi.nlm.nih.gov/pubmed/32979815 http://dx.doi.org/10.1016/j.compbiolchem.2020.107376

Ejemplares similares

Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches
por: Alamri, Mubarak A., et al.
Publicado: (2020)

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
por: Klemm, Theresa, et al.
Publicado: (2020)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach
por: Sencanski, Milan, et al.
Publicado: (2022)

Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro
por: Sokolinskaya, Elena L., et al.
Publicado: (2022)

SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions
por: Ershov, P. V., et al.
Publicado: (2023)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
por: Bajaj, Teena, et al.
Publicado: (2023)

Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes
por: Tan, Jinlin, et al.
Publicado: (2022)

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity
por: Kawall, Anasha, et al.
Publicado: (2023)

Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies
por: Ali Dahhas, Mohammed, et al.
Publicado: (2023)

Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Quantification of Berberine in Berberis vulgaris L. Root Extract and Its Curative and Prophylactic Role in Cisplatin-Induced In Vivo Toxicity and In Vitro Cytotoxicity
por: Ahmad, Sarfraz, et al.
Publicado: (2019)

Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro
por: Lewis, Devin S. M., et al.
Publicado: (2022)

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
por: Mirza, Muhammad Usman, et al.
Publicado: (2020)

Toxicity Evaluation of the Naphthalen-2-yl 3,5-Dinitrobenzoate: A Drug Candidate for Alzheimer Disease
por: Anwar, Fareeha, et al.
Publicado: (2021)

Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore‐based virtual screening approach
por: Mirza, Muhammad Usman, et al.
Publicado: (2020)

A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach
por: Rehman, Hafiz Muzzammel, et al.
Publicado: (2020)

Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow
por: Parmar, Paritosh, et al.
Publicado: (2021)

Corrigendum to ‘Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach’ [European Journal of Pharmaceutical Sciences 155 (2020) 105537]
por: Mirza, Muhammad Usman, et al.
Publicado: (2021)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021)

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022)

Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
por: Ferreira, Glaucio Monteiro, et al.
Publicado: (2022)

Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking
por: Castillo-Campos, Luis, et al.
Publicado: (2023)

Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation
por: Rao, Priyashi, et al.
Publicado: (2021)

Inhibitors of SARS-CoV-2 PLpro
por: Calleja, Dale J., et al.
Publicado: (2022)

Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
por: Maiti, Biplab K
Publicado: (2020)

Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
por: Li, Daoqun, et al.
Publicado: (2021)

In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
por: Elseginy, Samia A., et al.
Publicado: (2021)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

Isolation of Antidiabetic Withanolides from Withania coagulans Dunal and Their In Vitro and In Silico Validation
por: Maher, Saima, et al.
Publicado: (2020)

SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment
por: Stasiulewicz, Adam, et al.
Publicado: (2021)

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
por: Shan, Hengyue, et al.
Publicado: (2021)

Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
por: Li, Lingyu, et al.
Publicado: (2022)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

Crystal structure of SARS-CoV-2 papain-like protease
por: Gao, Xiaopan, et al.
Publicado: (2021)

Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from Pteris cretica L.
por: Saleem, Farooq, et al.
Publicado: (2019)

Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease
por: Bosken, Yuliana K., et al.
Publicado: (2020)

Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
por: Petushkova, Anastasiia I., et al.
Publicado: (2020)

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
por: Hersi, Fatema, et al.
Publicado: (2023)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1g1ktbeu1u7qfgdugpuvb1p4fd